Quantcast

Latest Multiple Myeloma Research Foundation Stories

2011-04-15 00:00:30

Composed of myeloma experts from China, Hong Kong, Taiwan, Japan, Rep. of Korea, Singapore, and Thailand, the IMF Asian Myeloma Network- the first of its kind in the region- will take the lead in projects to assist IMF in providing physician education and patient support throughout Asia. North Hollywood, CA (PRWEB) April 14, 2011 On March 17th the International Myeloma foundation (IMF) established the Asian Myeloma Network (AMN) at a meeting in Singapore. Composed of myeloma experts from...

2011-04-01 15:42:00

WHITE PLAINS, N.Y., April 1, 2011 /PRNewswire/ -- Once again, the Annual Report to the Nation on the Status of Cancer shows a continued decline in diagnoses and deaths for many types of cancers. This encouraging news can be attributed primarily to preventive measures such as cessation of smoking and improved diet, and early detection. (Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO ) But for many cancers, such as the blood cancers, early detection is rare, there are no...

2010-12-09 09:32:00

In early results, all participants responded to treatment with limited side effects ANN ARBOR, Mich., Dec. 9, 2010 /PRNewswire-USNewswire/ -- A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center. The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose...

b87993d1b33f05fb0360ed2a92fae0481
2010-12-09 10:45:43

In early results, all participants responded to treatment with limited side effects A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center. The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose dexamethasone. This is the first study to look at carfilzomib...

2010-12-07 08:12:00

In the news release, Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study, issued 07-Dec-2010 by Onyx Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the sixth paragraph, first sentence, should read "In a subset analysis of patients who were refractory to bortezomib in their last line of therapy (n=128), carfilzomib achieved an ORR of 19 percent and CBR of 31 percent" rather than " In a subset analysis of patients who were...

2010-12-07 06:30:00

EMERYVILLE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive complete results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved an overall response rate (ORR) (partial response or greater) of 24.1 percent and a median duration of response (DOR) of 8.3 months in patients who entered the study after...

2010-11-30 16:09:00

ORLANDO, Fla., Nov. 30, 2010 /PRNewswire/ -- Continuous or maintenance treatment is the new approach to cancer. Continuing treatment helps provide longer remissions and fewer relapses. This is made possible by new medications that can be taken and tolerated long-term. Multiple myeloma is one of the cancers that leads the way in this new approach to treatment. Hear directly from doctors and patients leading the way at a science journalist's workshop on the new paradigm of CONTINUOUS...

2010-08-04 15:28:00

Bio-Gal is Developing a Drug for the Treatment of Multiple Myeloma ("MM") Patients - Research and Clinical Observations of MM Terminal Patients by Bio-Gal Suggests That Treatment with Erythropoietin Suppresses the Disease, Prolonging and Improving the Patients' Lives. - XTL is Commencing Preparations to Begin a Phase 2 Clinical Trial in Multiple Myeloma Patients - Under the Transaction, XTL Received $1.5 Million in Cash XTL has announced that their...

2010-07-26 06:00:00

EMERYVILLE, Calif., July 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. In an independent review of the data, carfilzomib achieved an overall response rate (partial response or greater) of 24 percent and a median duration of response of 7.4 months in...

2010-04-12 05:15:00

Dr. Brian G.M. Durie, co-founder and chair of the International Myeloma Foundation (IMF), heads consortium of investigators across U.S. LOS ANGELES, April 12 /PRNewswire-USNewswire/ -- Aptium Oncology, Inc. today announced the launch of Aptium Oncology Myeloma Consortium (AMyC), a broad-based collaboration that brings together renowned investigators to work with pharmaceutical sponsors to advance clinical and translational research in myeloma and related cancers. Brian G.M. Durie, M.D.,...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related